Responses
Oral Presentations
WEDNESDAY, 12 JUNE 2019
RA therapy –JAK inhibitors and beyond
OP0029 SWITCHING BETWEEN THE JAK1-SELECTIVE INHIBITOR-UPADACITINIB AND ADALIMUMAB FOLLOWING INITIAL NON-RESPONSE: CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS
Compose a Response to This Article
Other responses
No responses have been published for this article.